Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 6.45 is 46% below its 5-year average of 12.02, near the low end of its 5-year range (4.18–24.26).
As of the fiscal period ended Tuesday, June 30, 2026. 15.61% below its 12-month average of 7.65.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.45.
CURRENT RATIO
6.45
CURRENT RATIO AVG TTM
7.65
CURRENT RATIO AVG 3Y
8.09
CURRENT RATIO AVG 5Y
12.02
CURRENT RATIO AVG 10Y
10.17
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-15.61%
CURRENT VS 3Y AVG
-20.19%
CURRENT VS 5Y AVG
-46.29%
CURRENT VS 10Y AVG
-36.53%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+72.12%
vs the sector median at left
Profound Medical Corp.
Market Cap
$222.57M
Current Ratio
6.45
TTM Avg
7.65
3Y Avg
8.09
5Y Avg
12.02
Market Cap
$222.70M
Current Ratio
21.96
TTM Avg
18.45
3Y Avg
17.11
5Y Avg
21.15
Market Cap
$214.63M
Current Ratio
344.31
TTM Avg
177.51
3Y Avg
95.19
5Y Avg
76.57
Market Cap
$214.64M
Current Ratio
4.07
TTM Avg
3.65
3Y Avg
6.88
5Y Avg
10.38
Market Cap
$214.10M
Current Ratio
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $222.57M | 6.45 | 7.65 | 8.09 | 12.02 |
| Keros Therapeutics, Inc. (KROS)vs › | $222.70M | 21.96 | 18.45 | 17.11 | 21.15 |
| Vogenx Inc. (VOGX)vs › | $230.00M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.63M | 344.31 | 177.51 | 95.19 | 76.57 |
| Biodesix, Inc. (BDSX)vs › | $229.14M | 2.85 | 2.31 | 2.04 | 2.06 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.64M | 4.07 | 3.65 | 6.88 | 10.38 |
| MacroGenics, Inc. (MGNX)vs › | $230.42M | 2.96 | 4.51 | 4.52 | 4.67 |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 6.50 | 4.21 | 3.36 | 3.03 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.10M | 5.36 | 6.17 | 11.50 | 11.99 |
| BioAge Labs Inc. (BIOA)vs › | $231.17M | 17.19 | 13.55 | 8.08 | 8.08 |
Current Ratio
6.45
Quick Ratio
5.31
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 6.45 |
| 2026-03-31 | 6.56 |
| 2025-12-31 | 12.52 |
| 2025-09-30 | 4.18 |
| 2025-06-30 | 8.53 |
| 2025-03-31 | 11.31 |
| 2024-12-31 | 10.52 |
| 2024-09-30 | 6.12 |
| 2024-06-30 | 8.61 |
| 2024-03-31 | 9.44 |
| 2023-12-31 | 6.58 |
| 2023-09-30 | 9.32 |
| 2023-06-30 | 4.98 |
| 2023-03-31 | 12.35 |
| 2022-12-31 | 14.82 |
| 2022-09-30 | 17.36 |
| 2022-06-30 | 19.64 |
| 2022-03-31 | 18.32 |
| 2021-12-31 | 18.56 |
| 2021-09-30 | 24.26 |
| 2021-06-30 | 21.91 |
| 2021-03-31 | 23.39 |
| 2020-12-31 | 20.32 |
| 2020-09-30 | 28.03 |
| 2020-06-30 | 14.06 |
| 2020-03-31 | 16.41 |
| 2019-12-31 | 2.77 |
| 2019-09-30 | 3.60 |
| 2019-06-30 | 3.71 |
| 2019-03-31 | 4.65 |
| 2018-12-31 | 6.55 |
| 2018-09-30 | 9.41 |
| 2018-06-30 | 4.23 |
| 2018-03-31 | 7.46 |
| 2017-12-31 | 1.64 |
| 2017-09-30 | 2.02 |
| 2017-06-30 | 2.37 |
| 2017-03-31 | 2.91 |
| 2016-12-31 | 4.54 |
| 2016-09-30 | 2.31 |
| 2016-06-30 | 4.17 |
| 2016-03-31 | 8.85 |
| 2015-12-31 | 16.52 |
| 2015-09-30 | 12.77 |
| 2015-06-30 | 13.29 |
| 2015-03-31 | 0.03 |
| 2014-12-31 | 14.32 |
| 2014-09-30 | 46.31 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
